

Patients	Full Treatment Response Achieved (n = 79)	Full Treatment Response Not Achieved (n = 237)	p
Age, mean \pm SD	44.92 \pm 12.55	46.29 \pm 2.75	0.005
>40 years, % (proportion)	63.3% (81/128)	46.9% (30/64)	0.03
Male, % (proportion)	77.3% (99/128)	85.9% (55/64)	0.159
Precore mutants, % (proportion)	59.2% (74/125)	40% (24/60)	0.014
Cirrhosis, % (proportion)	8.1% (10/123)	9.1% (5/55)	0.831
Presence of HIV co-infection, % (proportion)	32% (41/128)	46.9% (30/64)	0.045
Baseline CD4 cell count, cells/ μ L (range)	448 (151 – 1120)	492 (112 – 1197)	0.373
Tenofovir pre-treatment HBV median viral load, IU/mL (range)	1.6E+6 (20 – 1.6E+8)	1E+8 (3.2E+5 – 1.6E+8)	0.088
End of follow up HBeAg loss, % (proportion)	80.4% (37/46)	27.3% (9/33)	<0.001
Overall HBV treatment duration in years, mean \pm SD	7.53 \pm 3.17	9.87 \pm 3.95	0.642

Supplementary Table 1. Characteristic of patients based on treatment success.